It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Sarepta Therapeutics ...

Marketing and sales expenses increased by €2.8 million in 2024 compared to 2023, as 2024 represented the first full year of ...

Reports Q revenue EUR 165,789 vs EUR 63, 089 last year. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx (IFRX), ...

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as ...

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 ...

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Beyond the surface of your skin, eczema, psoriasis and more can majorly impact your self image and intimate relationships.

Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.